Positive results for new scan in prostate cancer
Defining the extent of prostate cancer spread in newly diagnosed patients is important for therapeutic decision making. A recent study showed that a new technique, called gallium-68 prostate-specific membrane antigen (PSMA) PET-CT, had significant benefits over conventional imaging with CT and bone scanning.
In the study, published in the Lancet, 300 men with newly diagnosed high-risk prostate cancer (Gleason score 3–5, PSA >2 or clinical stage 3) were randomised to either PSMA PET-CT or conventional scans and followed up for six months.
PSMA PET-CT showed a 27% absolute superiority in accuracy over conventional scanning (92% [CI: 88–95] versus 65% [CI: 60–69]).
28% of PSMA PET-CT scans let to management change compared to only 15% with conventional scanning, and the new scan also produced fewer unclear results (7% versus 23%).
As a single procedure the PSMA PET-CT scan also exposed patients to lower doses of radiation than the two scan conventional procedure (8mSv versus 19mSv).
Study lead, Professor Michael Hofman, says: ‘The study shows that PSMA PET-CT is a suitable replacement for CT and bone scanning, providing superior accuracy, greater impact on management change, fewer equivocal results and a lower radiation exposure.’